AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top
Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development has positioned Bristol Myers Squibb as a stronger player in the highly competitive and lucrative schizophrenia treatment market, as AbbVie’s setback gives Bristol Myers Squibb an unexpected advantage. AbbVie recently […]